Reuters logo
Pfizer pain drug Lyrica fails study in adolescents with fibromyalgia
March 12, 2015 / 9:22 PM / 3 years ago

Pfizer pain drug Lyrica fails study in adolescents with fibromyalgia

(Reuters) - Pfizer Inc’s pain drug, Lyrica, failed a post-marketing study testing the treatment in adolescents with fibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas.

A man walks past Pfizer's world headquarters in New York April 28, 2014. REUTERS/Andrew Kelly

Pfizer conducted the trial to meet U.S. Food and Drug Administration requirements after Lyrica was approved for the condition.

Lyrica, known chemically as pregabalin, is currently approved for various indications in 139 countries and regions.

The drug is also approved in the United States for neuropathic pain associated with diabetic peripheral neuropathy and spinal cord injuries, post-herpetic neuralgia, and partial onset seizures in patients with epilepsy who are already taking other drugs.

Reporting by Natalie Grover in Bengaluru; Editing by Simon Jennings

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below